2004
DOI: 10.1007/s00432-004-0583-6
|View full text |Cite
|
Sign up to set email alerts
|

Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study

Abstract: The adherence to CMF treatment guidelines was generally good. Simultaneous radiotherapy did not affect the median RDI of CMF. G-CSF had no impact on the median RDI but patient volume did influence the RDI.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 28 publications
0
5
0
Order By: Relevance
“…outcomes, the evidence is conflicting, because other studies have not reported similar survival benefits [12][13][14] . When therapy is considered palliative, none of the three major guideline organizations-the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer, and the U.S. National Comprehensive Cancer Network-has made a definitive recommendation 1,15,16 .…”
Section: Discussionmentioning
confidence: 99%
“…outcomes, the evidence is conflicting, because other studies have not reported similar survival benefits [12][13][14] . When therapy is considered palliative, none of the three major guideline organizations-the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer, and the U.S. National Comprehensive Cancer Network-has made a definitive recommendation 1,15,16 .…”
Section: Discussionmentioning
confidence: 99%
“…Still, they reported findings for two different subpopulations. Similarly, eleven retrospective studies used data from the National Cancer Registry of the Netherlands but analysed different regions or periods [40][41][42][43][44][45][46][47][48][49][50].…”
Section: Study Characteristicsmentioning
confidence: 99%
“…Five studies [37,38,49,54,74] addressed procedures aimed to prevent adverse events during treatment, including patients receiving treatment in the period between 1996 and 2017. The median adherence was 75% (IQR 63-75%, and ranged from 19 [46] to 96% [37]. These recommendations included (1) using antiemetics to avoid acute or delayed emesis induced by chemotherapy [37]; (2) applying measures to prevent surgical infections [46]; (3) using primary prophylaxis with granulocyte colony-stimulating factors in patients receiving chemotherapy [27]; (4) monitoring left ventricular ejection fraction (LVEF) during anti-HER2 therapy [76], and (5) indicating vitamin D and calcium in patients receiving adjuvant non-steroidal aromatase inhibitors [75].…”
Section: Supportive Measures During Therapiesmentioning
confidence: 99%
“…Additionally, prospective studies demonstrated that an increase in chemotherapy RDI resulted in an improvement of DFS and OS (Budman et al, 1998;Citron et al, 2003;Bonneterre et al, 2005). In spite of these clear data, several retrospective analyses evaluating adjuvant chemotherapy RDI in daily practices have shown a significant decrease in RDI, irrespective of country and chemotherapy regimen (Link et al, 2001;Morrow et al, 2002;Ottevanger et al, 2002;Leonard et al, 2003;Lyman et al, 2003;Schaapveld et al, 2004;Chirivella et al, 2006;Shayne et al, 2006). Among these analyses, 20-30% of patients received less than 85% of pre-planned chemotherapy schedule.…”
Section: Discussionmentioning
confidence: 99%